CKD Bio Corp. (063160.KS)
KRW 22500.0
(-1.96%)
KRW 22500.0
(-1.96%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -24.19 Billion KRW | -44.84% |
| 2022 | -16.7 Billion KRW | -153.97% |
| 2021 | -6.57 Billion KRW | -205.95% |
| 2020 | 6.2 Billion KRW | -49.39% |
| 2019 | 12.26 Billion KRW | 54.16% |
| 2018 | 7.95 Billion KRW | -0.75% |
| 2017 | 8.01 Billion KRW | -15.03% |
| 2016 | 9.43 Billion KRW | 41.81% |
| 2015 | 6.65 Billion KRW | 702.07% |
| 2014 | -1.1 Billion KRW | -166.67% |
| 2013 | 1.65 Billion KRW | -76.66% |
| 2012 | 7.1 Billion KRW | -34.97% |
| 2011 | 10.92 Billion KRW | -24.03% |
| 2010 | 14.37 Billion KRW | -11.17% |
| 2009 | 16.18 Billion KRW | 85.22% |
| 2008 | 8.73 Billion KRW | 366.93% |
| 2007 | -3.27 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 2.83 Billion KRW | 134.8% |
| 2024 Q2 | 4.4 Billion KRW | 55.52% |
| 2024 Q3 | 285 Million KRW | -93.53% |
| 2023 Q2 | -6.75 Billion KRW | -132.43% |
| 2023 Q4 | -8.13 Billion KRW | -27.18% |
| 2023 FY | -24.19 Billion KRW | -44.84% |
| 2023 Q1 | -2.9 Billion KRW | 58.93% |
| 2023 Q3 | -6.39 Billion KRW | 5.26% |
| 2022 Q3 | -3.5 Billion KRW | 28.91% |
| 2022 Q2 | -4.92 Billion KRW | -308.74% |
| 2022 Q1 | -1.2 Billion KRW | -44.47% |
| 2022 FY | -16.7 Billion KRW | -153.97% |
| 2022 Q4 | -7.07 Billion KRW | -102.11% |
| 2021 Q2 | 477.47 Million KRW | 124.36% |
| 2021 Q1 | -1.96 Billion KRW | -98.63% |
| 2021 Q3 | -4.25 Billion KRW | -992.19% |
| 2021 Q4 | -833.75 Million KRW | 80.43% |
| 2021 FY | -6.57 Billion KRW | -205.95% |
| 2020 Q1 | 2.47 Billion KRW | -28.63% |
| 2020 Q3 | 1.35 Billion KRW | -59.57% |
| 2020 Q4 | -986.91 Million KRW | -172.66% |
| 2020 FY | 6.2 Billion KRW | -49.39% |
| 2020 Q2 | 3.35 Billion KRW | 35.69% |
| 2019 Q1 | 2.29 Billion KRW | 29.83% |
| 2019 Q3 | 3.32 Billion KRW | 4.9% |
| 2019 Q4 | 3.46 Billion KRW | 4.26% |
| 2019 FY | 12.26 Billion KRW | 54.16% |
| 2019 Q2 | 3.17 Billion KRW | 38.22% |
| 2018 Q2 | 1.64 Billion KRW | -24.16% |
| 2018 Q3 | 2.36 Billion KRW | 43.9% |
| 2018 FY | 7.95 Billion KRW | -0.75% |
| 2018 Q1 | 2.17 Billion KRW | 144.55% |
| 2018 Q4 | 1.76 Billion KRW | -25.41% |
| 2017 Q1 | 2.17 Billion KRW | 18.05% |
| 2017 FY | 8.01 Billion KRW | -15.03% |
| 2017 Q4 | 887.96 Million KRW | -65.31% |
| 2017 Q3 | 2.55 Billion KRW | 6.84% |
| 2017 Q2 | 2.39 Billion KRW | 10.23% |
| 2016 FY | 9.43 Billion KRW | 41.81% |
| 2016 Q4 | 1.84 Billion KRW | 44.84% |
| 2016 Q3 | 1.27 Billion KRW | -58.67% |
| 2016 Q2 | 3.07 Billion KRW | -5.3% |
| 2016 Q1 | 3.24 Billion KRW | 51.48% |
| 2015 FY | 6.65 Billion KRW | 702.07% |
| 2015 Q2 | 845.77 Million KRW | 14.21% |
| 2015 Q3 | 2.92 Billion KRW | 245.59% |
| 2015 Q1 | 740.55 Million KRW | 547.69% |
| 2015 Q4 | 2.14 Billion KRW | -26.65% |
| 2014 Q3 | -194.66 Million KRW | 76.06% |
| 2014 Q2 | -813.28 Million KRW | -1290.56% |
| 2014 Q1 | 68.31 Million KRW | 146.34% |
| 2014 Q4 | -165.41 Million KRW | 15.02% |
| 2014 FY | -1.1 Billion KRW | -166.67% |
| 2013 FY | 1.65 Billion KRW | -76.66% |
| 2013 Q2 | 546.16 Million KRW | -24.54% |
| 2013 Q3 | 534.92 Million KRW | -2.06% |
| 2013 Q1 | 723.76 Million KRW | 25.99% |
| 2013 Q4 | -147.4 Million KRW | -127.56% |
| 2012 FY | 7.1 Billion KRW | -34.97% |
| 2012 Q4 | 574.47 Million KRW | -76.74% |
| 2012 Q3 | 2.46 Billion KRW | -3.3% |
| 2012 Q2 | 2.55 Billion KRW | 69.99% |
| 2012 Q1 | 1.5 Billion KRW | -53.28% |
| 2011 Q1 | 3.06 Billion KRW | -13.27% |
| 2011 FY | 10.92 Billion KRW | -24.03% |
| 2011 Q4 | 3.21 Billion KRW | 39.42% |
| 2011 Q3 | 2.3 Billion KRW | -1.01% |
| 2011 Q2 | 2.33 Billion KRW | -24.04% |
| 2010 Q3 | 5.53 Billion KRW | 116.49% |
| 2010 FY | 14.37 Billion KRW | -11.17% |
| 2010 Q2 | 2.55 Billion KRW | -6.91% |
| 2010 Q1 | 2.74 Billion KRW | 4.61% |
| 2010 Q4 | 3.53 Billion KRW | -36.1% |
| 2009 Q4 | 2.62 Billion KRW | -42.64% |
| 2009 FY | 16.18 Billion KRW | 85.22% |
| 2009 Q2 | 3.85 Billion KRW | -24.84% |
| 2009 Q1 | 5.12 Billion KRW | 12.14% |
| 2009 Q3 | 4.57 Billion KRW | 18.79% |
| 2008 Q3 | 2.85 Billion KRW | 572.52% |
| 2008 Q4 | 4.57 Billion KRW | 60.2% |
| 2008 Q1 | 887.37 Million KRW | 136.79% |
| 2008 FY | 8.73 Billion KRW | 366.93% |
| 2008 Q2 | 424.35 Million KRW | -52.18% |
| 2007 FY | -3.27 Billion KRW | 0.0% |
| 2007 Q3 | 175.33 Million KRW | 185.1% |
| 2007 Q1 | -830.45 Million KRW | 0.0% |
| 2007 Q2 | -206.03 Million KRW | 75.19% |
| 2007 Q4 | -2.41 Billion KRW | -1475.78% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | -7.18 Billion KRW | -236.901% |
| Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | 141.719% |
| Ildong Holdings Co., Ltd. | -59.58 Billion KRW | 59.4% |
| HANDOK Inc. | -28.79 Billion KRW | 15.991% |
| Kukje Pharma Co., Ltd. | -8.41 Billion KRW | -187.486% |
| Yuhan Corporation | 93.5 Billion KRW | 125.872% |
| Dong-A ST Co., Ltd. | 11.12 Billion KRW | 317.51% |
| SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | 2.497% |
| Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | 116.544% |
| Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | 789.519% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | -865.224% |
| Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | -1066.518% |
| MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | -434.661% |
| Hana Pharm Co., Ltd. | 22.33 Billion KRW | 208.327% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | -236.901% |
| Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | -15.528% |
| REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | 775.133% |
| Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 79.545% |
| JW Holdings Corporation | 19.02 Billion KRW | 227.153% |
| Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | 69.349% |
| Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 111.384% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 165.374% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 57.798% |
| Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | 495.189% |
| Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | 1554.28% |
| Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | 583.392% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | -236.901% |
| Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | 165.446% |
| Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | 121.697% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 165.374% |
| Yuhan Corporation | 93.5 Billion KRW | 125.872% |
| Jeil Pharma Holdings Inc | -16.24 Billion KRW | -48.879% |
| Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | -524.236% |
| Suheung Co., Ltd. | 6.11 Billion KRW | 495.353% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 165.374% |
| Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | 227.964% |
| Korea United Pharm Inc. | 48.26 Billion KRW | 150.128% |
| Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | 201.152% |
| Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | 188.171% |
| Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | 181.253% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 57.798% |
| Chong Kun Dang Holdings Corp. | 47 Billion KRW | 151.465% |
| Boryung Corporation | 40.2 Billion KRW | 160.176% |
| Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | 22.781% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | -865.224% |
| JW Lifescience Corporation | 28.14 Billion KRW | 185.96% |